Form 4: Ionis Pharmaceuticals CEO Brett P. Monia Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Ionis Pharmaceuticals CEO Brett P. Monia sold 38,843 shares of common stock on February 4, 2025, at a weighted average price of $31.6521, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 4, 2025, Brett P. Monia, CEO of Ionis Pharmaceuticals, sold 38,843 shares of Ionis Pharmaceuticals (IONS) common stock.
- The sale was executed at a weighted average price of $31.6521 per share.
- The shares were sold under a Rule 10b5-1 trading plan adopted on August 13, 2024.
- Following the transaction, Monia directly owns 180,683 shares of Ionis Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports a stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative news about the company's performance.
Future Outlook
There is no future outlook provided in this document.
Industry Context
This is a routine disclosure of an insider stock sale. Insider sales can sometimes be viewed negatively by the market, but the use of a pre-arranged 10b5-1 trading plan mitigates concerns about opportunistic trading based on inside information.
Comparison to Industry Standards
- Rule 10b5-1 trading plans are a common practice among corporate executives to sell shares in a compliant manner.
- The volume of shares sold is relatively small compared to the total outstanding shares of Ionis Pharmaceuticals.
- Similar sales are regularly disclosed by executives at comparable biotechnology companies such as Alnylam Pharmaceuticals and Biogen.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The use of a 10b5-1 plan should reassure stakeholders that the sale was not based on any non-public information.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date the reporting person adopted the Rule 10b5-1 Trading Plan |
| 02/04/2025 | Date of the transaction (stock sale) |
| 02/05/2025 | Date of signature on the Form 4 filing |
Keywords
Ionis Pharmaceuticals, Brett P. Monia, stock sale, Form 4, Rule 10b5-1, insider trading, IONS, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.